Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.46
RHHBY's Cash to Debt is ranked lower than
87% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. RHHBY: 0.46 )
Ranked among companies with meaningful Cash to Debt only.
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: N/A
Current: 0.46

Equity to Asset 0.26
RHHBY's Equity to Asset is ranked lower than
87% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RHHBY: 0.26 )
Ranked among companies with meaningful Equity to Asset only.
RHHBY' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.59
Current: 0.26

0.1
0.59
F-Score: 5
Z-Score: 3.82
M-Score: -2.79
WACC vs ROIC
8.98%
37.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.26
RHHBY's Operating margin (%) is ranked higher than
92% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. RHHBY: 28.26 )
Ranked among companies with meaningful Operating margin (%) only.
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 33.69
Current: 28.26

4.53
33.69
Net-margin (%) 18.71
RHHBY's Net-margin (%) is ranked higher than
87% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. RHHBY: 18.71 )
Ranked among companies with meaningful Net-margin (%) only.
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 18.71

-13.67
30.16
ROE (%) 49.73
RHHBY's ROE (%) is ranked higher than
97% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.55 vs. RHHBY: 49.73 )
Ranked among companies with meaningful ROE (%) only.
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 102.95
Current: 49.73

-16.17
102.95
ROA (%) 14.01
RHHBY's ROA (%) is ranked higher than
93% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. RHHBY: 14.01 )
Ranked among companies with meaningful ROA (%) only.
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 14.01

-5.78
17.58
ROC (Joel Greenblatt) (%) 71.03
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. RHHBY: 71.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 71.03

6.9
84.52
Revenue Growth (3Y)(%) 5.00
RHHBY's Revenue Growth (3Y)(%) is ranked higher than
54% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.10 vs. RHHBY: 5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.3   Max: 391.7
Current: 5

-2.3
391.7
EBITDA Growth (3Y)(%) 3.10
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. RHHBY: 3.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1   Max: 280
Current: 3.1

-5.1
280
EPS Growth (3Y)(%) -0.50
RHHBY's EPS Growth (3Y)(%) is ranked higher than
57% of the 410 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. RHHBY: -0.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -3.8   Max: 341.1
Current: -0.5

-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
Q3 2014

RHHBY Guru Trades in Q3 2014

Bill Frels 2,391,096 sh (+9.44%)
Ken Fisher 1,891,406 sh (+4.30%)
» More
Q4 2014

RHHBY Guru Trades in Q4 2014

Ken Fisher 2,823,025 sh (+49.26%)
Bill Frels 2,609,371 sh (+9.13%)
» More
Q1 2015

RHHBY Guru Trades in Q1 2015

Bill Frels 2,703,876 sh (+3.62%)
Ken Fisher 2,788,126 sh (-1.24%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.30
RHHBY's P/E(ttm) is ranked higher than
70% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 40.20 vs. RHHBY: 25.30 )
Ranked among companies with meaningful P/E(ttm) only.
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 36.39
Current: 25.3

13.05
36.39
Forward P/E 2.30
RHHBY's Forward P/E is ranked higher than
97% of the 311 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. RHHBY: 2.30 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.30
RHHBY's PE(NRI) is ranked higher than
68% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. RHHBY: 25.30 )
Ranked among companies with meaningful PE(NRI) only.
RHHBY' s 10-Year PE(NRI) Range
Min: 13.05   Max: 44.62
Current: 25.3

13.05
44.62
P/B 12.00
RHHBY's P/B is ranked lower than
86% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. RHHBY: 12.00 )
Ranked among companies with meaningful P/B only.
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 22.21
Current: 12

2.64
22.21
P/S 4.90
RHHBY's P/S is ranked higher than
77% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.17 vs. RHHBY: 4.90 )
Ranked among companies with meaningful P/S only.
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.45
Current: 4.9

2.38
6.45
PFCF 18.40
RHHBY's PFCF is ranked higher than
74% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. RHHBY: 18.40 )
Ranked among companies with meaningful PFCF only.
RHHBY' s 10-Year PFCF Range
Min: 8.6   Max: 39.65
Current: 18.4

8.6
39.65
POCF 14.80
RHHBY's POCF is ranked higher than
78% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 31.25 vs. RHHBY: 14.80 )
Ranked among companies with meaningful POCF only.
RHHBY' s 10-Year POCF Range
Min: 6.98   Max: 25.96
Current: 14.8

6.98
25.96
EV-to-EBIT 17.61
RHHBY's EV-to-EBIT is ranked higher than
76% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 30.27 vs. RHHBY: 17.61 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 17.61

7.9
32
PEG 6.66
RHHBY's PEG is ranked lower than
79% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. RHHBY: 6.66 )
Ranked among companies with meaningful PEG only.
RHHBY' s 10-Year PEG Range
Min: 0.3   Max: 7.66
Current: 6.66

0.3
7.66
Shiller P/E 24.50
RHHBY's Shiller P/E is ranked higher than
79% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 43.00 vs. RHHBY: 24.50 )
Ranked among companies with meaningful Shiller P/E only.
RHHBY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 110.34
Current: 24.5

13.35
110.34
Current Ratio 1.35
RHHBY's Current Ratio is ranked lower than
83% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. RHHBY: 1.35 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s 10-Year Current Ratio Range
Min: 1.35   Max: 3.75
Current: 1.35

1.35
3.75
Quick Ratio 1.01
RHHBY's Quick Ratio is ranked lower than
83% of the 806 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. RHHBY: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s 10-Year Quick Ratio Range
Min: 1.01   Max: 3.22
Current: 1.01

1.01
3.22
Days Inventory 182.80
RHHBY's Days Inventory is ranked lower than
70% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. RHHBY: 182.80 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s 10-Year Days Inventory Range
Min: 109.1   Max: 245.45
Current: 182.8

109.1
245.45
Days Sales Outstanding 65.90
RHHBY's Days Sales Outstanding is ranked lower than
53% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. RHHBY: 65.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s 10-Year Days Sales Outstanding Range
Min: 65.9   Max: 86.72
Current: 65.9

65.9
86.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.70
RHHBY's Dividend Yield is ranked higher than
87% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. RHHBY: 2.70 )
Ranked among companies with meaningful Dividend Yield only.
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 4.55
Current: 2.7

0.74
4.55
Dividend Payout 0.73
RHHBY's Dividend Payout is ranked lower than
83% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. RHHBY: 0.73 )
Ranked among companies with meaningful Dividend Payout only.
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.72
Current: 0.73

0.21
0.72
Dividend growth (3y) 5.70
RHHBY's Dividend growth (3y) is ranked lower than
53% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. RHHBY: 5.70 )
Ranked among companies with meaningful Dividend growth (3y) only.
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: 5.7

0
27.3
Yield on cost (5-Year) 4.06
RHHBY's Yield on cost (5-Year) is ranked higher than
90% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. RHHBY: 4.06 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 1.11   Max: 6.84
Current: 4.06

1.11
6.84
Share Buyback Rate -0.50
RHHBY's Share Buyback Rate is ranked higher than
87% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: -10.70 vs. RHHBY: -0.50 )
Ranked among companies with meaningful Share Buyback Rate only.
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.80
RHHBY's Price/DCF (Projected) is ranked higher than
81% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. RHHBY: 1.80 )
Ranked among companies with meaningful Price/DCF (Projected) only.
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.27   Max: 7.13
Current: 1.8

1.27
7.13
Price/Median PS Value 1.20
RHHBY's Price/Median PS Value is ranked higher than
58% of the 784 Companies
in the Global Biotechnology industry.

( Industry Median: 2.00 vs. RHHBY: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 1.27
Current: 1.2

0.64
1.27
Earnings Yield (Greenblatt) 5.50
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
94% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. RHHBY: 5.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 5.5

3.1
12.7
Forward Rate of Return (Yacktman) 8.63
RHHBY's Forward Rate of Return (Yacktman) is ranked lower than
63% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 14.93 vs. RHHBY: 8.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 79.2
Current: 8.63

2.2
79.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico,
Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
Roche In Expansion Mode Jan 19 2015 
Why Organovo is A Safe Buy? Dec 18 2014 

More From Other Websites
ASCO targets war on cancer May 29 2015
Xenon Pharmaceuticals to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare... May 28 2015
Xenon Pharmaceuticals to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare... May 28 2015
Halozyme, Ventana Enter Into Global Agreement To Collaboratively Develop Companion Diagnostic For... May 27 2015
Roche receives FDA clearance for the cobas® Cdiff Test to detect Clostridium difficile May 26 2015
Roche Shows Strength in Face of Uncertainty May 25 2015
Why Denali Raised A $217 Million Financing Round: Not Just 'Because It Could' May 21 2015
Can Roche Win From The War On Lung Cancer? UBS Thinks So May 18 2015
Roche Reports Encouraging Data on Lung Cancer Drugs - Analyst Blog May 14 2015
ASCO's immunotherapies update May 14 2015
Genentech’s Investigational Immunotherapy MPDL3280A Doubled the Likelihood of Survival Compared... May 13 2015
Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With... May 13 2015
Possible Investment Contest May 13 2015
Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update May 12 2015
Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update May 12 2015
Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO May 11 2015
Roche Receives FDA Approval for cobas® KRAS Mutation Test May 11 2015
Genentech Announces New STEM Education Initiative to Support South San Francisco Schools May 04 2015
[$$] In Battle Against Alzheimer’s, This May Be Ground Zero Apr 28 2015
New Prenatal DNA Test For Down Syndrome Dramatically Reduces Errors Apr 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK